Fierce Pharma
JUNE 15, 2023
While demand for COVID-19 vaccines has plummeted throughout 2023, healthcare officials remain focused on ensuring that the most effective shots are available for those who need them. | While demand for COVID-19 vaccines has plummeted throughout 2023, healthcare officials remain focused on ensuring that the most effective shots are available for those who need them.
MedCity News
JUNE 15, 2023
Medivis recently raised $20 million in a Series A funding round that included investments from Mayo Clinic, Bob Iger and Kevin Durant. The New York City-based company’s technology can be thought of as a “virtual GPS system” for surgeons — it helps them navigate complex anatomical landscapes during operations and gives them a more accurate, intuitive understanding of the anatomy with which they’re dealing.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
JUNE 15, 2023
As biosimilars gradually gain steam in the U.S. market, one of the biggest manufacturers of the copycat biologics has unveiled a plan to boost uptake across the globe. | Sandoz' Act4Biosimilars action plan includes a detailed report of challenges preventing wider biosimilar access in each region, starting with the Americas. The initiative's steering group will work with stakeholders across the region to implement steps to boost uptake.
Pharmaceutical Technology
JUNE 15, 2023
Eloxx has revealed its lead candidate ELX-02 improved predicted forced expiratory volume (ppFEV1) in patients with Class 1 cystic fibrosis (CF) in a new analysis of a Phase II trial that missed its efficacy endpoints. Following underwhelming topline results from the Phase II trial (NCT04135495) announced in late 2022, Eloxx recalculated the results using the change in ppFEV1 (a secondary outcome) from day 1 instead of from baseline.
Fierce Pharma
JUNE 15, 2023
An announcement early this month by Mark Cuban’s deep discount drug company that it would sell Coherus Biosciences’ biosimilar version of AbbVie’s Humira has the Illinois drugmaker calling foul.
MedCity News
JUNE 15, 2023
President Jimmy Carter’s decision to opt for hospice care has highlighted the importance of hospice care. His choice will hopefully help Americans better understand the benefits of hospice and lead to discussions with providers and loved ones about desired goals of care when approaching the end of life. But while hospice may be a newer topic of discussion for some, those of us who work to provide this type of health care have long understood the positive impact it has on patients, families and t
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Legacy MEDSearch
JUNE 15, 2023
Cala , the bioelectronic medicine leader setting a new standard of care for chronic disease, today announced the commercial launch of its next generation system: the Cala kIQ System, the first and only FDA-cleared wearable device that delivers effective therapy for action hand tremor relief in people with essential tremor and Parkinson’s disease. The Cala kIQ System delivers Cala TAPS (Transcutaneous Afferent Patterned Stimulation) therapy, which is validated by large clinical studies and real-w
Fierce Pharma
JUNE 15, 2023
AbbVie has opened a new front in its blood cancer drug rivalry against BeiGene. | AbbVie has opened a new front in its BTK blood cancer drug rivalry against BeiGene. In a lawsuit, the Illinois pharma giant accuses BeiGene of infringing a U.S. patent that was just issued on Tuesday.
MedCity News
JUNE 15, 2023
Most patients prefer in-person care to virtual, according to a recent report. This finding should drive health systems to refine their telehealth experiences — they should determine which type of visits are best-suited for the modality, and they should ensure their virtual care environments adopt a more human-centric design.
Fierce Pharma
JUNE 15, 2023
After acing a study for the induction treatment of ulcerative colitis, AbbVie’s Skyrizi has snatched another win in a maintenance trial. An approval now looks within reach for 2024. | After acing a study for the induction treatment of ulcerative colitis, AbbVie’s Skyrizi has delivered another win in a maintenance trial. An approval now looks within reach for 2024.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MedCity News
JUNE 15, 2023
Eli Lilly’s partnership with Verve Therapeutics covers the development of a preclinical therapy addressing a protein associated with cardiovascular disease risk. The in vivo gene-editing therapy is a potential one-time treatment.
Fierce Pharma
JUNE 15, 2023
In this episode of "The Top Line," we talk with Fierce’s Max Bayer and Angus Liu about the most important news coming from this year's annual BIO conference. | This week on "The Top Line," we discuss the the top news from this year's annual BIO meeting, plus a COVID lawsuit, an FDA-approved app and the rest of the week's headlines.
MedCity News
JUNE 15, 2023
Now that Medicaid redeterminations have resumed, Walgreens is supporting patients by educating them about renewals and helping them navigate through the process, execs said at AHIP 2023 in Portland.
European Pharmaceutical Review
JUNE 15, 2023
A paper published in the Journal of Pharmaceutical Research International has reviewed microbiological testing for medical devices and described their applications and challenges. Microbiological testing is essential for quality control , regulatory compliance and can help minimise the risk of microbial contamination. This approach can also help determine the appropriate manufacturing processes, sterilisation methods, and maintenance procedures.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
MedCity News
JUNE 15, 2023
In an environment where capital isn’t as easy to access, INVEST Digital Health conference will seek to arm you with the right connections and meaningful insight to navigate an environment where ROI is king. Hear from payers, providers, startups, life sciences executives, VCs and more.
PharmaTimes
JUNE 15, 2023
Researchers show silver retains antimicrobial activity for longer when it is infused into bioactive glass - News - PharmaTimes
MedCity News
JUNE 15, 2023
For the second time in three months, Mersana Therapeutics is dealing with an FDA clinical hold. The partial hold on tests of its experimental ovarian cancer drug follows a full hold placed on an early-stage test of a different Mersana therapy in various types of solid tumors.
PharmaTimes
JUNE 15, 2023
EO2463 is an experimental treatment for indolent non-Hodgkin B cell lymphoma - News - PharmaTimes
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
MedCity News
JUNE 15, 2023
But what AI solutions can’t do is magically eliminate the need for empowered registrars. Maximizing growth while improving efficiency requires both people and technologies.
PharmExec
JUNE 15, 2023
Webinar Date/Time: Wed, Jul 26, 2023 11:00 AM EDT
Copyright Clearance Center
JUNE 15, 2023
The post The Supreme Court Case of Andy Warhol Foundation v. Goldsmith: What, if Anything, Does it Mean to Artificial Intelligence? appeared first on Copyright Clearance Center.
Clarify Health
JUNE 15, 2023
It’s impossible to run a successful accountable care organization (ACO) without data interoperability. Interconnected data is vital for many facets of ACOs, including patient information, care coordination, quality measurement, population health management, value-based reimbursement, research, and analytics. By facilitating the seamless exchange and utilization of data, strong interoperability standards enhance an organization’s ability to deliver accountable, patient-centered care
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
PharmaTech
JUNE 15, 2023
Compendia publications are periodically updated in order to align with industry trends and harmonize with global regulatory practices. Staying abreast of these changes well before they are implemented, and being ready to adapt as necessary, is in the best interest of any bio/pharmaceutical testing laboratory. Eurofins BioPharma Product Testing has proactively adjusted its procedures, collaborating with stakeholders and providing feedback to ensure smooth integration and minimal impact on existin
Spotio
JUNE 15, 2023
Listen to the episode on Spotify. How to Build A World-Class Coaching Program for Field Sales With Sebastian Jimenez Sebastian Jimenez, the mastermind behind Rillavoice, the speech recording and analytics software for external sales and service teams, joins us to share invaluable tips and insights on creating an exceptional coaching program for field sales experts.
PharmaTech
JUNE 15, 2023
The integration of the binders into a routine lateral flow test will support the clinical and commercial development of rapid diagnostics for Alzheimer’s disease through nasal sampling.
Pharmaceutical Technology
JUNE 15, 2023
Japan-based Astellas Pharma has entered a partnership with Cullgen to discover and develop multiple targeted protein degraders through the latter’s proprietary uSMITE targeted protein degradation platform, in a deal potentially worth $1.9bn. Under the agreement, Astellas will give an upfront payment of $35m to the San Diego-based biotech, Cullgen. The deal gives Astellas the option to exclusively license its rights for clinical development and commercialisation for any protein degrader compounds
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Clarivate
JUNE 15, 2023
For patent and trademark offices, law firms and corporations seeking to automate intellectual property operations and optimize decision making, artificial intelligence is now considered business critical. In this blog, Vashe Kanesarajah, Head of Strategy, IP Organization at Clarivate, explores how artificial intelligence (AI) and machine learning (ML) are progressing and what this means for the intellectual property ecosystem.
PharmaTech
JUNE 15, 2023
The investment, which is taking place in Hillerød, Denmark, will aim to create more production capacity and increase the company’s ability to meet future market demands and to continue development on its future clinical late-phase product portfolio.
European Pharmaceutical Review
JUNE 15, 2023
According to a report by Future Market Insights, the small molecule innovator contract development and manufacturing organisation (CDMO) market is projected to value $48.09 billion in 2023 and $89.43 billion in 2033. Sales in the small molecule innovator CDMO market is expected to grow at a compound annual growth rate (CAGR) of 6.4 percent during the forecast period.
Pharmaceutical Technology
JUNE 15, 2023
Alentis Therapeutics has received US Food and Drug Administration (FDA) clearance for its investigational new drug (IND) application for ALE.C04 to treat Claudin-1 positive (CLDN1+) tumours. ALE.C04 is an investigational antibody designed to target exposed CLDN1 in cancer cells. This approval has been granted for ALE.C04 both as a monotherapy and in combination with pembrolizumab in a first-in-human clinical study in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
222 
Let's personalize your content